My Locations
Part of the Duke Cancer Institute
Part of the Duke Cancer Institute
About Me
I specialize in the care of people with genitourinary (GU) cancers, which includes cancer of the kidney, bladder, prostate, testicles, and penis. As medical oncology providers, my team and I use medications to treat cancer, like immunotherapy, pill therapies and chemotherapy. My team and I provide comprehensive cancer care, and we treat symptoms from cancer and/or the side effects from treatment. We work closely with surgeons, radiation oncologists, and other clinicians to provide the best and most individualized treatment strategy for each patient. A cancer diagnosis and everything that comes with it can be one of the most stressful events in someone’s life. I chose this specialty to support patients and their loved ones during these difficult times. I firmly believe in understanding the goals of my patients at the outset, constantly re-evaluating these goals, and working with patients to choose the course that most closely aligns with those goals.
- Assistant Professor of Medicine, Medicine, Medical Oncology 2023
- Member of the Duke Cancer Institute, Duke Cancer Institute 2024
Call for an Appointment
Ratings and Reviews
The ratings and reviews are based on patient responses to the overall provider rating question from the survey. The question reads: “Using any number from 0 to 10, where 0 is the worst provider possible and 10 is the best provider possible, what number would you use to rate this provider?” Responses are converted to a 5-point rating system and applied consistently to all providers. Learn more about our survey process. Patients who see some types of providers receive a different version of the patient satisfaction survey. Those results are not available on DukeHealth.org.
Training and Education
Clinical Focus and Research
My research focuses on the development of new treatments for patients with genitourinary cancers, which includes prostate, kidney, bladder, penis, and testicular cancers. My goal is to help develop better treatment options for patients through clinical trials. I am also interested in discovering and studying genes that make someone more likely to get cancer in the first place, so we can ultimately identify people who are at higher risk and stop cancers before they spread.
-
EvoPAR-Prostate01: AZD5305 vs placebo in men with mCSPCIRB# PRO00114544 , NCT# NCT06120491
- Candelieri-Surette, Danielle, Anna Hung, Fatai Y. Agiri, Mengke Hu, Elizabeth E. Hanchrow, Kyung Min Lee, Nai-Chung N. Chang, et al. “Incorporating Structured and Unstructured Data Sources to Identify and Characterize Hereditary Cancer Testing Among Veterans With Metastatic Castration-Resistant Prostate Cancer.” JCO Clin Cancer Inform 9 (February 2025): e2400189. https://doi.org/10.1200/CCI-24-00189.
- Cheng, Heather H., Jeffrey W. Shevach, Elena Castro, Fergus J. Couch, Susan M. Domchek, Rosalind A. Eeles, Veda N. Giri, et al. “BRCA1, BRCA2, and Associated Cancer Risks and Management for Male Patients: A Review.” JAMA Oncol 10, no. 9 (September 1, 2024): 1272–81. https://doi.org/10.1001/jamaoncol.2024.2185.
- Shevach, Jeffrey W., Danielle Candelieri-Surette, Julie A. Lynch, Rebecca A. Hubbard, Patrick R. Alba, Karen Glanz, Ravi B. Parikh, and Kara N. Maxwell. “Racial Differences in Germline Genetic Testing Completion Among Males With Pancreatic, Breast, or Metastatic Prostate Cancers.” J Natl Compr Canc Netw 22, no. 4 (April 17, 2024): 237–43. https://doi.org/10.6004/jnccn.2023.7105.
- Shevach, J., B. K. Marcellino, W. K. Oh, and C. K. Tsao. “Enzalutamide in metastatic castration resistant prostate cancer.” In Managing Metastatic Prostate Cancer In Your Urological Oncology Practice, 157–69, 2016. https://doi.org/10.1007/978-3-319-31341-2_10.
- Shevach, J., and K. Martin. “Overuse of HIT antibody testing in clinical practice.” In HAEMOPHILIA, 25:66–66, 2019.
- Bossert, Adam, Jeffrey Shevach, Richard Bakst, Jerry Liu, Krzysztof Misiukiewicz, Jessica Beyda, Brett Miles, Eric Genden, Marshall R. Posner, and Vishal Gupta. “(S024) Extracapsular Extension Is Associated With Worse Distant Control and Progression-Free Survival in Patients With Lymph Node-Positive Human Papillomavirus-Related Oropharyngeal Carcinoma.” In International Journal of Radiation Oncology*Biology*Physics, 98:E8–E8. Elsevier BV, 2017. https://doi.org/10.1016/j.ijrobp.2017.02.060.
- Shevach, Jeffrey, Emily Gallagher, Teena Kochukoshy, Victoria Gresia, Manpreet Brar, Matt D. Galsky, and William K. Oh. “Influence of concurrent diabetes mellitus on clinical progression and response to androgen deprivation therapy in patients with advanced prostate cancer.” In Journal of Clinical Oncology, 33:e16036–e16036. American Society of Clinical Oncology (ASCO), 2015. https://doi.org/10.1200/jco.2015.33.15_suppl.e16036.
Insurance Accepted
Duke Health contracts with most major health insurance carriers and transplant networks, including the ones listed below.
-
Aetna
- Aetna Choice POS, Aetna Choice POS II
- Aetna Elect Choice HMO, Aetna Open Access Elect Choice
- Aetna Health Network Only, Aetna Health Network Option
- Aetna HMO
- Aetna Limited Benefit Insurance PPO
- Aetna Managed Choice POS
- Aetna Medicare Assure Plan (HMO D-SNP)
- Aetna Medicare Eagle Plan (PPO)
- Aetna Medicare Essential Plan (PPO)
- Aetna Medicare Value Plan (HMO)
- Aetna Open Access HMO, Open Access Aetna Select, Aetna Open Access Managed Choice
- Aetna Open Choice PPO
- Aetna PCP Coordinated POS Plan
- Aetna Quality Point of Service (QPOS)
- Aetna Select HMO
- Aetna Traditional Choice
- Aetna Voluntary Indemnity Group Plan
- Aetna Whole Health – Duke WakeMed WKCC
- Aetna/CVS Health
-
Ambetter
- Ambetter of North Carolina
-
Blue Cross Blue Shield of NC
- Blue Advantage
- Blue Medicare (HMO, PPO)*
- Blue Options (123, PPO, HSA)
- Blue Select
- NC State Employees Health Plan
-
*Duke HomeCare and Hospice does not participate in the plan.
-
Cigna
- Cigna Behavioral Health (*Limited eligibility)
- Cigna Choice Plus
- Cigna Connect Individual Family Plan
- Cigna Open Access
- Cigna Open Access Plus
-
*Please call Cigna Behavioral Heath to see if the provider is participating in your plan.
-
Duke Group Plans
- Duke Basic
- Duke Select
-
Experience Health
- Experience Health Medicare Advantage (HMO) Plan
- Gateway Health Alliance
- Healthgram
-
Humana
- Humana Choice (PPO)
- Humana Choice - Medicare Advantage (PPO)
- Humana ChoiceCare - Medicare Advantage (PPO)
- Humana Gold Choice - Medicare Advantage (PFFS)
- Humana Gold Plus - Medicare Advantage (HMO)
- Humana Medicare Advantage Group Plan - NC State Retirees
- MedCost
-
Medicare
- First Medicare Direct
- Medicare Part A
- Medicare Part B
-
NC Medicaid
- AmeriHealth Caritas North Carolina
- Carolina Complete Health
- Healthy Blue
- NC Medicaid Direct
- WellCare of North Carolina
-
TRICARE
- TRICARE Prime
- TRICARE Prime Remote
- TRICARE Select
-
United Healthcare
- AARP Medicare Advantage Plan 2 (HMO-POS)
- AARP Medicare Complete (HMO, PPO)*
- AARP Medicare Complete Essential (HMO)*
- All Savers Alternate Funding
- All Savers Fully Insured
- United Healthcare (HMO, PPO, POS)**
- United Healthcare Charter/Charter Balance/Charter Plus
- United Healthcare Choice/Choice Plus
- United Healthcare Core/Core Essential
- United Healthcare Navigate/Navigate Plus/Navigate Balanced
- United Healthcare Option PPO
- United Healthcare Passport Connect Choice/Choice Plus
- United Healthcare Passport Connect Options PPO
- United Healthcare Select/Select Plus
- United Healthcare Shared Services - Harvard Pilgrim/UHC Options PPO Network
- United Medical Resources (UMR)
-
*Duke HomeCare and Hospice and mental health providers do not participate with the plan.
-
**Duke Health does not participate in UHC plans on the Health Insurance Marketplace.
Before scheduling your appointment, we strongly recommend you contact your insurance company to verify that the Duke Health location or provider you plan to visit is included in your network. Your insurance company will also be able to inform you of any co-payments, co–insurances, or deductibles that will be your responsibility. If you proceed in scheduling an appointment and your health insurance benefits do not participate with Duke, your out of pocket liability may be higher. We will contact you regarding your coverage and patient liability. If you are uninsured, learn more about our financial assistance policy.
External Relationships
- AstraZeneca
- Bayer
- Dava Oncology
- MJH Life Sciences
- Merck Sharpe & Dohme (Merck & Co, USA)
- Pfizer Inc.